arthritis drug Actemra. Biogen (NASDAQ:BIIB), which obtained regulatory and commercial rights to Tofidence from the Chinese biotech Bio-Thera Solutions in 2021, launched the monoclonal antibody ...

Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients. The FDA approved ...

Actemra (tocilizumab) is a prescription drug that’s used to treat certain inflammatory conditions. This drug can interact with some other medications. For example, Actemra can interact with ...

Manufactured and marketed by Biogen with the formal generic name of tocilizumab-bavi, the new product will compete with Roche/Genentech's blockbuster original, Actemra. But Tofidence won't sport ...

Actemra (tocilizumab) is a prescription drug that’s used to treat arthritis and other conditions. Actemra’s cost may depend on factors such as your dosage, whether you have health insurance ...

Actemra is the first FDA-approved monoclonal antibody for treating patients with severe COVID-19, providing an important option for hospitalized patients and their healthcare providers who ...

--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Actemra ...

Roche RHHBY announced that the FDA has accepted the company’s supplemental biologics license application (sBLA) for its arthritis drug Actemra. The sBLA is seeking approval for the intravenous ...

If approved, Actemra would be the first U.S. FDA-approved immunomodulator for the treatment of COVID-19 in hospitalized patients – – Since the beginning of the pandemic, more than one million people ...

The World Health Organization (WHO) has issued a prequalification for Roche’s Actemra/RoActemra (tocilizumab). This means the treatment meets the WHO standards for quality, effectiveness and safety ...